494223-75-5

Upstream product

• 1365178-59-1 methyl 2-(3-oxopropyl)oxazole-4-carboxylate 
• 1355026-77-5 ethyl (4R,5E,7S)-4-amino-7-hydroxy-8-(3-methylphenyl)-5-octenoate hydrochloride 
• 233750-49-7 methyl 3-hydroxy-2-[(4-{tert-butyldiphenylsilyloxy}butanoyl)amino]propanoate 
• 233750-51-1 methyl 2-(3-{tert-butyldiphenylsilyloxy}propyl)-1,3-oxazole-4-carboxylate 
• 1355026-82-2 methyl 2-(3-{(2R)-2-[(1E,3S)-3-hydroxy-4-(3-methylphenyl)-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}propyl)-1,3-oxazole-4-carboxylate 
• 1355026-76-4 ethyl (4R,5E,7S)-8-(3-methylphenyl)-7-hydroxy-4-({tert-butyloxycarbonyl}amino)-5-octenoate 
• 1355026-81-1 methyl 2-(3-hydroxypropyl)-1,3-oxazole-4-carboxylate 
• 494224-49-6 (R)-ethyl 4-(tert-butoxycarbonylamino)-5-oxopentanoate 
• 597577-78-1 (4R)-4-t-butoxycarbonylamino-5-hydroxypentanoic acid ethyl ester 

Relevant academic research and scientific papers

Discovery of novel prostaglandin analogs as potent and selective EP2/EP4 dual agonists

To identify potent EP2/EP4 dual agonists with excellent subtype selectivity, a series of γ-lactam prostaglandin E analogs bearing a 16-phenyl ω-chain were synthesized and evaluated. Structural hybridization of 1 and 2, followed by more detailed chemical m

REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT

A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound